MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on November 30, 2006; DOI: 10.1124/mol.106.028902

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.028902v1
71/3/787    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kempna, P.
Right arrow Articles by Fluck, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kempna, P.
Right arrow Articles by Fluck, C. E.


Received for publication July 19, 2006.
Revised November 26, 2006.
Accepted for publication November 30, 2006.

PIOGLITAZONE INHIBITS ANDROGEN PRODUCTION IN NCI-H295R CELLS BY REGULATING GENE EXPRESSION OF CYP17 AND HSD3B2

Petra Kempna 1, Gaby Hofer 1, Primus E. Mullis 1, Christa E. Fluck 2*

1 Univ Children's Hosp Bern 2 University Children's Hospital Bern

* Address correspondence to: E-mail: christa.flueck{at}insel.ch

Abstract

Thiazolidinediones (TZD) such as pioglitazone and rosiglitazone are widely used as insulin sensitizers in the treatment of type 2 diabetes. In diabetic women with polycystic ovary syndrome (PCOS), treatment with pioglitazone or rosiglitazone improves insulin resistance and hyperandrogenism, but the mechanism by which TZDs downregulate androgen production is unknown. Androgens are synthesized in the human gonads as well as the adrenals. We studied the regulation of androgen production by analysing the effect of pioglitazone and rosiglitazone on steroidogenesis in human adrenal NCI-H295R cells, an established in vitro model of steroidogenesis of the human adrenal cortex. Both TZDs changed the steroid profile of the NCI-H295R cells and inhibited the activities of P450c17 and 3{beta}HSDII, key enzymes of androgen biosynthesis. Pioglitazone but not rosiglitazone inhibited the expression of the CYP17 and HSD3B2 genes. Similarly, pioglitazone repressed basal and 8Br-cAMP-stimulated activities of CYP17 and HSD3B2 promoter reporters in NCI-H295R cells. However, pioglitazone did not change the activity of a cAMP responsive luciferase reporter indicating that it does not influence cAMP/PKA/CREBP signaling. Although PPAR{gamma} is the nuclear receptor for TZDs, suppression of PPAR{gamma} by siRNA technique did not alter the inhibitory effect of pioglitazone on CYP17 and HSD3B2 expression, suggesting that pioglitazone's action is independent of PPAR{gamma}. On the other hand treatment of NCI-H295R cells with MEK/ERK inhibitor PD98059 enhanced promoter activity and expression of CYP17. This effect was reversed by pioglitazone treatment, indicating that the MEK/ERK signaling pathway plays a role in regulating androgen biosynthesis by pioglitazone.


Key words: Sex hormones, PPARs, MAP Kinase, Regulation - transcriptional, Endocrine cells


This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
A. Hoeflich and M. Bielohuby
Mechanisms of adrenal gland growth: signal integration by extracellular signal regulated kinases1/2
J. Mol. Endocrinol., March 1, 2009; 42(3): 191 - 203.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
E. Samandari, P. Kempna, J.-M. Nuoffer, G. Hofer, P. E Mullis, and C. E Fluck
Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3{beta}-hydroxysteroid dehydrogenase type 2 and 17,20 lyase activities
J. Endocrinol., December 1, 2007; 195(3): 459 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet
Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics